TLRY
Tilray Brands, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.03
−0.33%Year over year
Reported trailing growth
- Revenue
- -10.9%
- EBITDA
- +99.4%
- EBIT
- +97.5%
- EPS
- +95.6%
- Free cash flow
- +4.9%
- Operating cash flow
- -5.5%
Forward estimates
Based on analyst estimates
- Revenue
- +15.8%
- EBITDA
- +397.3%
- EPS
- +78.1%
Three-year CAGR
- Revenue
- +2.7%
- EBITDA
- +100.4%
- EBIT
- +97.2%
- Net income
- +94.4%
- EPS
- +95.6%
- Free cash flow
- +41.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Aug 1, 2026